ENSC (Ensysce Biosciences) Ending Cash Position: $0.75 Mil (As of Mar. 2026)


ENSC Ensysce Biosciences Inc ENSC
23 GF Score
Price $0.27
! 2 Warning Signs
View Full Analysis

What is Ensysce Biosciences Ending Cash Position?

Ensysce Biosciences ENSC -2.56% 23 Ending Cash Position is $0.75 Mil as of Mar. 2026. GuruFocus rates ENSC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Ensysce Biosciences's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.75 Mil.

Ensysce Biosciences's quarterly Ending Cash Position increased from Sep. 2025 ($1.67 Mil) to Dec. 2025 ($4.31 Mil) but then declined from Dec. 2025 ($4.31 Mil) to Mar. 2026 ($0.75 Mil).

Ensysce Biosciences's annual Ending Cash Position increased from Dec. 2023 ($1.12 Mil) to Dec. 2024 ($3.50 Mil) and increased from Dec. 2024 ($3.50 Mil) to Dec. 2025 ($4.31 Mil).

Ensysce Biosciences Ending Cash Position Related Terms

Ensysce Biosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Ensysce Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ensysce Biosciences Ending Cash Position Chart

Ensysce Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 12.27 3.15 1.12 3.50 4.31

Ensysce Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.05 2.21 1.67 4.31 0.75
ENSC
23GF Score
Ensysce Biosciences Inc ENSC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ensysce Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Ensysce Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.502+0.808
=4.31

Ensysce Biosciences's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.31+-3.565
=0.75

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.75 Mil mean?
Ensysce Biosciences (ENSC) has a Ending Cash Position of $0.75 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ensysce Biosciences and its competitors.
Is Ensysce Biosciences' Ending Cash Position too high?
Ensysce Biosciences' current Ending Cash Position is $0.75 Mil. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' Ending Cash Position compare to RNAZ and ALZN?
Ensysce Biosciences' Ending Cash Position of $0.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ensysce Biosciences and its competitors. Ensysce Biosciences's current Ending Cash Position is $0.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSC) has a current Ending Cash Position of $0.75 Mil. The current Ending Cash Position is $0.75 Mil. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Ensysce Biosciences (ENSC), the current Ending Cash Position is $0.75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ensysce Biosciences Business Description

Address 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score

Get the complete analysis for ENSC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27
Price